Amarin Shares Rise 2.75%

Shares of red-hot biotech firm Amarin Corp. AMRN are rallying again on Thursday. The stock is up another 2.75% to $19.05. Over the last 5 trading sessions, AMRN has jumped around 12%. The company is developing a cardiovascular drug called AMR101, which has shown positive results in two Phase III clinical trials. The chatter on Wall Street suggests that Amarin is a likely takeout target due to AMR101. Amarin Corporation plc (Amarin) is a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease.